66 terminated. 66 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 66 | Terminated 66 |
| Phase 2 | 12 | Terminated 12 |
Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure Clozapine, Esketamine Nasal Product, Escitalopram - Schizophrenia and Related Disorders, Major Depressive Disorder | Phase 3 | Terminated | Dr. Inge Winter | 1 | 2025-04-27 | 2026-11-05 |
| A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Terminated | Janssen Research & Development, LLC | 47 | 2024-09-19 | 2026-06-08 |
| SAINT for MDD in an Inpatient Setting Follow-on Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Terminated | Janssen Research & Development, LLC | 101 | 2024-06-26 | 2026-02-17 |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501 NMRA-335140 - Major Depressive Disorder | Phase 3 | Terminated | Neumora Therapeutics, Inc. | 904 | 2023-11-10 | 2026-09-14 |
| Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD REL-1017, Placebo - Major Depressive Disorder, Depression | Phase 3 | Terminated | Levomecor Inc. | 27 | 2023-08-17 | 2026-07-10 |
| A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) Aticaprant - Depressive Disorder, Major | Phase 3 | Terminated | Janssen Research & Development, LLC | 871 | 2022-09-22 | 2026-10-06 |
| A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) REL-1017, Placebo - Major Depressive Disorder, Depression | Phase 3 | Terminated | Levomecor Inc. | 236 | 2021-03-30 | 2026-07-10 |
| A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy Seltorexant, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Janssen Research & Development, LLC | 212 | 2020-09-15 | 2025-06-04 |
| A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder SAGE-217, Placebo - Major Depressive Disorder | Phase 3 | Terminated | Biogen | 53 | 2019-08-06 | 2023-11-29 |
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy Ketamine infusion, Midazolam infusion - Major Depressive Disorder | Phase 2 / Phase 3 | Terminated | Yale University | 3 | 2019-07-17 | 2023-04-24 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia SAGE-217, Placebo - Major Depressive Disorder, Insomnia | Phase 3 | Terminated | Biogen | 87 | 2019-02-04 | 2023-11-29 |
| Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder Ziprasidone, Placebo - Bipolar Disorder | Phase 3 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 23 | 2018-12-21 | 2021-06-16 |
| Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD) Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 50 | 2018-10-30 | 2020-07-28 |
| Modafinil's Effects on Cognition in Remitted MDD Modafinil, Placebo - Major Depressive Disorder, Cognitive Impairment | Phase 3 | Terminated | Unity Health Toronto | 9 | 2018-10-15 | 2019-08-08 |
| Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) Rapastinel - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 230 | 2018-08-23 | 2020-07-17 |
| A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) ALKS 5461 - Refractory Major Depressive Disorder | Phase 3 | Terminated | Alkermes, Inc. | 175 | 2018-08-09 | 2021-07-16 |
| Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 363 | 2018-08-02 | 2020-10-09 |
| Study of Rapastinel as Monotherapy in Patients With MDD Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 439 | 2018-06-15 | 2020-09-01 |
Showing 20 of 66. Sign in to see all of them.
Depressive Disorder, Major (38) · Depression (28) · Bipolar Disorder (22) · Depressive Disorder (8) · Psychotic Disorders (3) · Schizophrenia (3) · Sleep Initiation and Maintenance Disorders (3) · Anhedonia (2) · Depression, Postpartum (2) · Metabolic Syndrome (2) · Motor Activity (2) · Parasomnias (2) · Suicidal Ideation (2) · Affective Disorders, Psychotic (1) · Alzheimer Disease (1)
Mental Disorders (66) · Depressive Disorder (40) · Behavior (29) · Behavioral Symptoms (29) · Bipolar and Related Disorders (22) · Nervous System Diseases (6) · Schizophrenia Spectrum and Other Psychotic Disorders (5) · Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Dyssomnias (3) · Glucose Metabolism Disorders (3) · Self-Injurious Behavior (3) · Sleep Disorders, Intrinsic (3) · Sleep Wake Disorders (3)
Escitalopram (8) · Aripiprazole (6) · GLYX-13 peptide (4) · Lithium (4) · ziprasidone (4) · Aticaprant (3) · Lisdexamfetamine Dimesylate (3) · Quetiapine Fumarate (3) · brexpiprazole (3) · ramelteon (3) · Exercise (2) · Fluoxetine (2) · Ketamine (2) · Lithium Carbonate (2) · Mifepristone (2)
Janssen Research & Development, LLC (4) · Naurex, Inc, an affiliate of Allergan plc (4) · Otsuka Pharmaceutical Development & Commercialization, Inc. (4) · H. Lundbeck A/S (3) · Lindner Center of HOPE (3) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (3) · Biogen (2) · Levomecor Inc. (2) · Magnus Medical (2) · Stanford University (2) · Takeda (2) · University Hospitals Cleveland Medical Center (2) · University of Texas Southwestern Medical Center (2) · Alkermes, Inc. (1) · AstraZeneca (1)
United States (44) · Canada (11) · Poland (11) · Germany (8) · Bulgaria (7) · Hungary (7) · France (6) · Spain (6) · Brazil (5) · Finland (5) · Mexico (5) · Slovakia (5) · Sweden (5) · Argentina (4) · Chile (4)
Jenna Hoogerheyde (4) · Brandon Bentzley, MD (2) · Keming Gao, MD, PhD (2) · Paul Greene, PhD (2) · Anja Braschoss, MD (1) · Birgit Ekholm, MD (1) · Bjorn Backe, MD PhD (1) · Chad D Rethorst, Ph.D. (1) · Christina Dording, MD (1)
PMID 35394365, PMID 14702256, PMID 18671864, PMID 20861739, PMID 21199966, PMID 24086352, PMID 25340384, PMID 26683252, PMID 28662460, PMID 31307859, PMID 34611902, PMID 34787653, PMID 36282771, PMID 37244205, PMID 37920963, PMID 41401709
2008 (2), 2018 (2), 2009 (1), 2019 (1), 2023 (1), R01MH125160 (1), R21MH062650 (1)